XML 58 R46.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Information and Concentration of Business Risk, Segment Information (Details)
$ in Thousands, shares in Millions
1 Months Ended 3 Months Ended 9 Months Ended
Oct. 31, 2018
shares
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2018
USD ($)
Segment
Sep. 30, 2017
USD ($)
Apr. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
USD ($)
Jul. 31, 2017
Segment Information and Concentration of Business Risk [Abstract]                  
Number of reportable segments | Segment       2          
Segment Information [Abstract]                  
Revenue   $ 145,395 $ 118,314 $ 407,559 $ 346,387        
Total operating expenses   163,967 107,002 479,716 309,140        
Income (loss) from operations   (18,572) 11,312 (72,157) 37,247        
Total assets as of current period   2,247,913   2,247,913       $ 1,322,774  
Commercial Revenue [Member]                  
Segment Information [Abstract]                  
Revenue   82,756 34,617 181,975 66,106        
SPINRAZA Royalties [Member]                  
Segment Information [Abstract]                  
Revenue   70,010 32,890 167,743 60,467        
Licensing and Other Royalties [Member]                  
Segment Information [Abstract]                  
Revenue   12,746 1,727 14,232 5,639        
R&D Revenue Under Collaborative Agreements [Member]                  
Segment Information [Abstract]                  
Revenue   $ 62,639 83,697 $ 225,584 280,281        
Akcea [Member]                  
Segment Information [Abstract]                  
Percentage ownership   75.00%   75.00%   75.00% 68.00%   68.00%
Akcea [Member] | Subsequent Event [Member]                  
Segment Information [Abstract]                  
Percentage ownership 76.00%                
Additional shares of Akcea stock received when TEGSEDI received marketing authorization in the U.S. (in shares) | shares 1.7                
Operating Segments [Member] | Ionis Core [Member]                  
Segment Information [Abstract]                  
Revenue   $ 178,061 108,408 $ 410,025 379,082        
Total operating expenses   87,664 81,019 279,084 242,753        
Income (loss) from operations   90,397 27,389 130,941 136,329        
Total assets as of current period   2,446,425   2,446,425       1,342,578  
Operating Segments [Member] | Ionis Core [Member] | Commercial Revenue [Member]                  
Segment Information [Abstract]                  
Revenue   77,956 34,617 177,175 66,106        
Operating Segments [Member] | Ionis Core [Member] | SPINRAZA Royalties [Member]                  
Segment Information [Abstract]                  
Revenue   70,010 32,890 167,743 60,467        
Operating Segments [Member] | Ionis Core [Member] | Licensing and Other Royalties [Member]                  
Segment Information [Abstract]                  
Revenue   7,946 1,727 9,432 5,639        
Operating Segments [Member] | Ionis Core [Member] | R&D Revenue Under Collaborative Agreements [Member]                  
Segment Information [Abstract]                  
Revenue   100,105 73,791 232,850 312,976        
Operating Segments [Member] | Akcea Therapeutics [Member]                  
Segment Information [Abstract]                  
Revenue   19,241 9,906 54,670 21,712        
Total operating expenses   84,249 26,013 213,428 120,884        
Income (loss) from operations   (65,008) (16,107) (158,758) (99,172)        
Total assets as of current period   379,128   379,128       268,804  
Operating Segments [Member] | Akcea Therapeutics [Member] | Commercial Revenue [Member]                  
Segment Information [Abstract]                  
Revenue   12,000 0 12,000 0        
Operating Segments [Member] | Akcea Therapeutics [Member] | SPINRAZA Royalties [Member]                  
Segment Information [Abstract]                  
Revenue   0 0 0 0        
Operating Segments [Member] | Akcea Therapeutics [Member] | Licensing and Other Royalties [Member]                  
Segment Information [Abstract]                  
Revenue   12,000 0 12,000 0        
Operating Segments [Member] | Akcea Therapeutics [Member] | R&D Revenue Under Collaborative Agreements [Member]                  
Segment Information [Abstract]                  
Revenue   7,241 9,906 42,670 21,712        
Elimination of Intercompany Activity [Member]                  
Segment Information [Abstract]                  
Revenue   (51,907) 0 (57,136) (54,407)        
Total operating expenses   (7,946) (30) (12,796) (54,497)        
Income (loss) from operations   (43,961) 30 (44,340) 90        
Total assets as of current period   (577,641)   (577,641)       $ (288,608)  
Elimination of Intercompany Activity [Member] | Commercial Revenue [Member]                  
Segment Information [Abstract]                  
Revenue   (7,200) 0 (7,200) 0        
Elimination of Intercompany Activity [Member] | SPINRAZA Royalties [Member]                  
Segment Information [Abstract]                  
Revenue   0 0 0 0        
Elimination of Intercompany Activity [Member] | Licensing and Other Royalties [Member]                  
Segment Information [Abstract]                  
Revenue   (7,200) 0 (7,200) 0        
Elimination of Intercompany Activity [Member] | R&D Revenue Under Collaborative Agreements [Member]                  
Segment Information [Abstract]                  
Revenue   $ (44,707) $ 0 $ (49,936) $ (54,407)